Results of a multi-generational case study strengthen the case for genetic screening in cases of hereditary thyroid cancer.
Todd Kunkler
Advertisement
Articles by Todd Kunkler
Patients are more likely to present with regional or distant metastases and experience lower rates of cancer-free survival depending on where they live.
Researchers find that overexpression of a specific gene is associated with poor survival in patients with adrenocortical carcinoma.
FDA approvad Lazanda (fentanyl) nasal spray for the management of breakthrough pain in adult cancer patients.
Advertisement
Latest Updated Articles
FDA Approves First Fentanyl Nasal Spray for Breakthrough Cancer PainPublished: July 12th 2011 | Updated:
Genetic Data Points to Potential New Therapeutic Target for Adrenocortical CarcinomaPublished: May 29th 2012 | Updated:
Researchers Find Regional Differences in Stage of Presentation and Survival of Individuals With Thyroid CancerPublished: May 29th 2012 | Updated:
Carriers of Mutation Responsible for Multiple Endocrine Neoplasia Can Face Difficult ChoicesPublished: May 29th 2012 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes
4
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
5